Concept scores are derived automatically based on a person's publications. Keywords in the their attributed publications are matched to keywords from the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). The strength of a person's concept scores is based not only on the number of corresponding publications, but also how relevant the concepts are to the overall topics of the publications, how long ago the publications were written, whether the person was the first or senior author, and how many other people have written about the topic.Concepts cannot be directly edited. You can help ensure your concepts are accurate by making sure your attributed publications are correct and up-to-date. We recommend checking over your attributed publications list every three to four months.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Urinary Bladder Neoplasms | 7 | 2022 | 155 | 3.190 |
Why?
|
| Penile Neoplasms | 6 | 2021 | 45 | 3.130 |
Why?
|
| Carcinoma, Squamous Cell | 5 | 2021 | 318 | 2.030 |
Why?
|
| Carcinoma, Transitional Cell | 3 | 2022 | 52 | 1.610 |
Why?
|
| Kidney Neoplasms | 5 | 2021 | 177 | 1.570 |
Why?
|
| Prostatic Neoplasms | 3 | 2020 | 394 | 1.570 |
Why?
|
| Lymphocytes, Tumor-Infiltrating | 3 | 2021 | 78 | 1.480 |
Why?
|
| Neoplasm Recurrence, Local | 5 | 2023 | 614 | 1.260 |
Why?
|
| Carcinoma, Renal Cell | 4 | 2021 | 105 | 1.040 |
Why?
|
| Neoplasm Staging | 4 | 2023 | 740 | 0.940 |
Why?
|
| Immunotherapy | 6 | 2021 | 238 | 0.900 |
Why?
|
| Pheochromocytoma | 1 | 2023 | 35 | 0.900 |
Why?
|
| DNA Mismatch Repair | 1 | 2023 | 17 | 0.890 |
Why?
|
| Adrenal Gland Neoplasms | 1 | 2023 | 51 | 0.890 |
Why?
|
| Colonic Neoplasms | 1 | 2023 | 161 | 0.790 |
Why?
|
| Urothelium | 1 | 2021 | 18 | 0.760 |
Why?
|
| BCG Vaccine | 2 | 2020 | 16 | 0.740 |
Why?
|
| Neoadjuvant Therapy | 5 | 2022 | 114 | 0.730 |
Why?
|
| Indocyanine Green | 1 | 2020 | 34 | 0.730 |
Why?
|
| Cancer Vaccines | 1 | 2021 | 78 | 0.720 |
Why?
|
| Ubiquitin Thiolesterase | 2 | 2021 | 18 | 0.710 |
Why?
|
| CD8-Positive T-Lymphocytes | 1 | 2021 | 116 | 0.710 |
Why?
|
| Adjuvants, Immunologic | 1 | 2020 | 51 | 0.690 |
Why?
|
| Patient Readmission | 1 | 2021 | 219 | 0.680 |
Why?
|
| Anesthesia, Local | 1 | 2019 | 15 | 0.680 |
Why?
|
| Immunotherapy, Adoptive | 1 | 2021 | 156 | 0.670 |
Why?
|
| Male | 24 | 2023 | 25241 | 0.670 |
Why?
|
| Tumor Suppressor Proteins | 2 | 2021 | 128 | 0.670 |
Why?
|
| Edetic Acid | 1 | 2019 | 14 | 0.670 |
Why?
|
| Ureteral Neoplasms | 1 | 2019 | 12 | 0.660 |
Why?
|
| Prostate-Specific Antigen | 1 | 2019 | 47 | 0.650 |
Why?
|
| Papillomavirus Infections | 1 | 2021 | 155 | 0.650 |
Why?
|
| Testicular Neoplasms | 4 | 2021 | 63 | 0.650 |
Why?
|
| Oligopeptides | 1 | 2019 | 89 | 0.630 |
Why?
|
| Cystectomy | 3 | 2022 | 49 | 0.570 |
Why?
|
| Humans | 30 | 2023 | 49974 | 0.570 |
Why?
|
| Retrospective Studies | 10 | 2023 | 6108 | 0.560 |
Why?
|
| Arteriovenous Fistula | 1 | 2016 | 22 | 0.550 |
Why?
|
| Middle Aged | 12 | 2023 | 12069 | 0.530 |
Why?
|
| Aged | 11 | 2023 | 9310 | 0.510 |
Why?
|
| Neoplasms, Germ Cell and Embryonal | 3 | 2021 | 35 | 0.490 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 4 | 2022 | 989 | 0.470 |
Why?
|
| Lymphatic Metastasis | 4 | 2021 | 224 | 0.430 |
Why?
|
| Prognosis | 4 | 2023 | 1942 | 0.420 |
Why?
|
| Neoplasm Grading | 4 | 2020 | 123 | 0.410 |
Why?
|
| Female | 14 | 2023 | 26472 | 0.390 |
Why?
|
| Neoplasm Invasiveness | 3 | 2022 | 267 | 0.390 |
Why?
|
| Tumor Microenvironment | 3 | 2021 | 212 | 0.370 |
Why?
|
| Aged, 80 and over | 3 | 2023 | 3129 | 0.340 |
Why?
|
| Lymph Nodes | 2 | 2021 | 260 | 0.320 |
Why?
|
| Adult | 9 | 2023 | 13236 | 0.300 |
Why?
|
| Treatment Outcome | 7 | 2022 | 5141 | 0.290 |
Why?
|
| Postoperative Complications | 3 | 2021 | 984 | 0.240 |
Why?
|
| Neoplasm Metastasis | 3 | 2021 | 231 | 0.240 |
Why?
|
| Quality of Life | 2 | 2020 | 836 | 0.230 |
Why?
|
| Adrenalectomy | 1 | 2023 | 34 | 0.230 |
Why?
|
| Adrenal Glands | 1 | 2023 | 39 | 0.230 |
Why?
|
| Risk Factors | 2 | 2023 | 3613 | 0.220 |
Why?
|
| Deoxycytidine | 1 | 2022 | 27 | 0.210 |
Why?
|
| Retroperitoneal Space | 2 | 2021 | 30 | 0.210 |
Why?
|
| Cohort Studies | 3 | 2021 | 1422 | 0.200 |
Why?
|
| Muscles | 1 | 2022 | 103 | 0.200 |
Why?
|
| Mycobacterium bovis | 1 | 2021 | 11 | 0.190 |
Why?
|
| Antigens, Differentiation, Myelomonocytic | 1 | 2021 | 39 | 0.190 |
Why?
|
| Lymph Node Excision | 2 | 2021 | 134 | 0.190 |
Why?
|
| Teratoma | 1 | 2021 | 25 | 0.190 |
Why?
|
| Interleukin-2 | 1 | 2021 | 72 | 0.190 |
Why?
|
| Aftercare | 1 | 2021 | 75 | 0.190 |
Why?
|
| T-Lymphocytes | 2 | 2020 | 338 | 0.190 |
Why?
|
| Reference Standards | 1 | 2020 | 56 | 0.180 |
Why?
|
| Tomography, Emission-Computed | 1 | 2020 | 53 | 0.180 |
Why?
|
| Fluorouracil | 1 | 2020 | 54 | 0.180 |
Why?
|
| Cisplatin | 1 | 2022 | 278 | 0.180 |
Why?
|
| Lymphocyte Activation | 1 | 2021 | 172 | 0.180 |
Why?
|
| Recurrence | 2 | 2019 | 652 | 0.180 |
Why?
|
| Carcinoma in Situ | 1 | 2020 | 73 | 0.180 |
Why?
|
| Antigens, CD | 1 | 2021 | 219 | 0.170 |
Why?
|
| Sentinel Lymph Node Biopsy | 1 | 2020 | 116 | 0.170 |
Why?
|
| Survival Rate | 2 | 2019 | 894 | 0.170 |
Why?
|
| Gallium Isotopes | 1 | 2019 | 2 | 0.170 |
Why?
|
| Gallium Radioisotopes | 1 | 2019 | 10 | 0.170 |
Why?
|
| Kidney Pelvis | 1 | 2019 | 17 | 0.170 |
Why?
|
| Patient Discharge | 1 | 2021 | 320 | 0.160 |
Why?
|
| Inflammation | 1 | 2023 | 604 | 0.160 |
Why?
|
| Disease-Free Survival | 1 | 2020 | 454 | 0.160 |
Why?
|
| Feasibility Studies | 1 | 2020 | 375 | 0.160 |
Why?
|
| Papillomavirus Vaccines | 1 | 2019 | 61 | 0.160 |
Why?
|
| Genomics | 1 | 2020 | 286 | 0.160 |
Why?
|
| Urologic Neoplasms | 1 | 2018 | 12 | 0.160 |
Why?
|
| Ureteral Obstruction | 1 | 2019 | 60 | 0.160 |
Why?
|
| Carcinoma, Papillary | 1 | 2018 | 48 | 0.150 |
Why?
|
| Antineoplastic Agents | 3 | 2020 | 1171 | 0.150 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2020 | 510 | 0.150 |
Why?
|
| Cells, Cultured | 1 | 2021 | 1573 | 0.140 |
Why?
|
| Biopsy | 1 | 2019 | 584 | 0.140 |
Why?
|
| Cell Proliferation | 1 | 2021 | 1007 | 0.140 |
Why?
|
| Renal Artery | 1 | 2016 | 33 | 0.140 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 2020 | 828 | 0.140 |
Why?
|
| Nephrectomy | 1 | 2016 | 83 | 0.130 |
Why?
|
| Time Factors | 2 | 2020 | 2903 | 0.130 |
Why?
|
| Urinary Tract Infections | 1 | 2015 | 52 | 0.120 |
Why?
|
| Prospective Studies | 1 | 2020 | 2364 | 0.120 |
Why?
|
| Laparoscopy | 1 | 2016 | 170 | 0.120 |
Why?
|
| Kidney Transplantation | 1 | 2015 | 175 | 0.110 |
Why?
|
| Kidney Failure, Chronic | 1 | 2015 | 198 | 0.110 |
Why?
|
| Chemotherapy, Adjuvant | 2 | 2020 | 119 | 0.090 |
Why?
|
| Kaplan-Meier Estimate | 2 | 2021 | 466 | 0.080 |
Why?
|
| Follow-Up Studies | 3 | 2020 | 2182 | 0.080 |
Why?
|
| Survival Analysis | 2 | 2021 | 653 | 0.080 |
Why?
|
| T-Lymphocyte Subsets | 1 | 2021 | 39 | 0.050 |
Why?
|
| Immune System | 1 | 2021 | 44 | 0.050 |
Why?
|
| Administration, Topical | 1 | 2020 | 56 | 0.050 |
Why?
|
| Forkhead Transcription Factors | 1 | 2021 | 112 | 0.050 |
Why?
|
| Urinary Bladder | 1 | 2020 | 92 | 0.050 |
Why?
|
| Patient Selection | 1 | 2020 | 253 | 0.040 |
Why?
|
| Treatment Failure | 1 | 2019 | 114 | 0.040 |
Why?
|
| Macrophages | 1 | 2021 | 363 | 0.040 |
Why?
|
| Socioeconomic Factors | 1 | 2020 | 581 | 0.040 |
Why?
|
| Oncolytic Virotherapy | 1 | 2017 | 16 | 0.040 |
Why?
|
| Health Facilities | 1 | 2017 | 42 | 0.040 |
Why?
|
| Combined Modality Therapy | 1 | 2018 | 637 | 0.030 |
Why?
|
| Adolescent | 2 | 2019 | 6356 | 0.030 |
Why?
|
| Turkey | 1 | 2015 | 17 | 0.030 |
Why?
|
| Mutation | 1 | 2021 | 1294 | 0.030 |
Why?
|
| Clinical Trials as Topic | 1 | 2017 | 461 | 0.030 |
Why?
|
| Registries | 1 | 2017 | 522 | 0.030 |
Why?
|
| Child | 2 | 2019 | 6847 | 0.030 |
Why?
|
| Graft Survival | 1 | 2015 | 150 | 0.030 |
Why?
|
| Cytokines | 1 | 2017 | 612 | 0.030 |
Why?
|
| Antibodies, Monoclonal | 1 | 2017 | 459 | 0.030 |
Why?
|
| Child, Preschool | 1 | 2019 | 3871 | 0.020 |
Why?
|
| Mice | 1 | 2020 | 5739 | 0.020 |
Why?
|
| Young Adult | 1 | 2018 | 3958 | 0.020 |
Why?
|
| United States | 1 | 2017 | 4860 | 0.020 |
Why?
|
| Animals | 1 | 2020 | 13187 | 0.020 |
Why?
|